Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|July 18, 2019
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonistsLaura Muñoz-Moreno, María J Carmena, Andrew V Schally, et al.
The Prostate|March 24, 2022
Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH)Laura Muñoz-Moreno, M José Carmena, Juan C Prieto, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2002
Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in ratsJudit E Horvath, Ana M Bajo, Andrew V Schally, et al.
Anti-Cancer Drugs|October 24, 2002
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207Jose M Arencibia, Ana M Bajo, Andrew V Schally, et al.
The Prostate|May 12, 2018
Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancerLaura Muñoz-Moreno, Andrew V Schally, Juan C Prieto, et al.
The Prostate|February 4, 2009
Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cellsAna B Fernández-Martínez, Ana M Bajo, Manuel Sánchez-Chapado, et al.
Molecular and Cellular Endocrinology|November 6, 2012
Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinomaEva Vacas, Ana M Bajo, Andrew V Schally, et al.
Peptides|September 25, 2012
Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cellsEva Vacas, Ana M Bajo, Andrew V Schally, et al.
Molecular and Cellular Endocrinology|December 23, 2008
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cellsAna Valdehita, Ana M Bajo, Andrew V Schally, et al.
Cellular Signalling|December 3, 2014
VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cellsAna B Fernández-Martínez, María J Carmena, Ana M Bajo, et al.
Pageof 5